Grape King Bio (TPE:1707) EBIT : NT$2,676 Mil (TTM As of Dec. 2024)

View and export this data going back to 1982. Start your Free Trial

What is Grape King Bio EBIT?

Grape King Bio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was NT$821 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$2,676 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Grape King Bio's annualized ROC % for the quarter that ended in Dec. 2024 was 24.96%. Grape King Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 41.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Grape King Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 14.47%.

Grape King Bio EBIT Historical Data

The historical data trend for Grape King Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grape King Bio EBIT Chart

Grape King Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

2,392.53

2,418.92

2,690.25

2,663.16

2,676.34

Grape King Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial															862.95	485.97	591.54	777.82	821.02

Competitive Comparison of Grape King Bio's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grape King Bio's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Grape King Bio's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Grape King Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2,676 Mil.

Grape King Bio (TPE:1707) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Grape King Bio's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	3050.932 * ( 1 - 18.13% )	/	( (10052.431	+	9962.826)	/ 2 )
=	2497.7980284	/	10007.6285
=	24.96 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14405.899	-	2417.87	-	( 3382.616	-	max(0, 2657.206	-	4592.804	+	3382.616	))
=	10052.431

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15323.638	-	3087.681	-	( 4432.013	-	max(0, 3323.043	-	5596.174	+	4432.013	))
=	9962.826

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Grape King Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	3284.076	/	( ( (7944.367 + max(-1410.737, 0))	+	(7885.529 + max(-2135.643, 0)) )	/	2 )
=	3284.076	/	( ( 7944.367	+	7885.529 )	/	2 )
=	3284.076	/	7914.948
=	41.49 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(285.365	+	810.223	+	94.852)	-	(2417.87	+	0	+	183.307)
=	-1410.737

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(304.821	+	754.451	+	74.18)	-	(3087.681	+	0	+	181.414)
=	-2135.643

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Grape King Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	2676.341	/	18499.348
	=	14.47 %

Grape King Bio EBIT Related Terms

Thank you for viewing the detailed overview of Grape King Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Grape King Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grape King Bio Ltd (TPE:1707) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 402, Jinling Road, Section 2, Pingzhen District, Taoyuan, TWN, 324

Website

https://www.grapeking.com.tw

Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in the production and sales of pharmaceutical preparation, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the Company's development and manufacturing products for Pro-partner Inc, Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others and it derives a majority of its revenue from Taiwan.

Grape King Bio Headlines

No Headlines